These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8297119)

  • 1. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
    Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
    Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basis for the anti-tumor and chemopreventive activities of glucarate and the glucarate:retinoid combination.
    Abou-Issa H; Dwivedi C; Curley RW; Kirkpatrick R; Koolemans-Beynen A; Engineer FN; Humphries KA; el-Masry W; Webb TE
    Anticancer Res; 1993; 13(2):395-9. PubMed ID: 8517653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
    Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
    Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
    Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
    Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
    Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
    Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
    Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
    McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
    Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
    Parrett ML; Abou-Issa HM; Alshafie G; Ross MS; Harris RE; Robertson FM
    Anticancer Res; 1999; 19(6B):5079-85. PubMed ID: 10697514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapeutic evaluation of glucarate and N-(4-hydroxyphenyl)retinamide alone and in combination in the rat mammary tumor model.
    Abou-Issa H; Webb TE; Minton JP; Moeschberger M
    J Natl Cancer Inst; 1989 Dec; 81(23):1820-3. PubMed ID: 2531231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats.
    Allred CD; Allred KF; Ju YH; Clausen LM; Doerge DR; Schantz SL; Korol DL; Wallig MA; Helferich WG
    Carcinogenesis; 2004 Feb; 25(2):211-8. PubMed ID: 14578162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
    Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
    Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of retinoids on growth and metastasis of hamster melanoma in athymic mice.
    Schleicher RL; Moon RC; Patel MK; Beattie CW
    Cancer Res; 1988 Mar; 48(6):1465-9. PubMed ID: 3345519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
    Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
    Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
    Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
    Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal but not carcinomatous primary rat mammary epithelium: readily transplanted to and maintained in the athymic nude mouse.
    Welsch CW; O'Connor DH; Aylsworth CF; Sheffield LG
    J Natl Cancer Inst; 1987 Mar; 78(3):557-65. PubMed ID: 3102827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
    Thun-Battersby S; Mevissen M; Löscher W
    Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumour synergism between non-toxic dietary combinations of isotretinoin and glucarate.
    Abou-Issa H; Koolemans-Beynen A; Meredith TA; Webb TE
    Eur J Cancer; 1992; 28A(4-5):784-8. PubMed ID: 1388036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
    Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
    Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.